Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | PREP | P48147 | 4/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4674934 | 0.87 | HTR2C (0.52) | KLK7KLK5PREPNPSR1HTR2C | |
| SCHEMBL3017853 | 0.84 | HTR2C (0.52) | PREPCTSKNPSR1TSHRL3MBTL1 | |
| SCHEMBL6501753 | 0.84 | HTR2C (0.52) | PREPCTSKNPSR1TSHRL3MBTL1 | |
| SCHEMBL6487292 | 0.84 | HTR2C (0.52) | PREPCTSKNPSR1TSHRL3MBTL1 | |
| SCHEMBL7251746 | 0.84 | HTR2C (0.53) | PREPNPSR1TSHRL3MBTL1HTR2C | |
| SCHEMBL8220722 | 0.84 | HTR2C (0.53) | PREPNPSR1TSHRL3MBTL1HTR2C | |
| SCHEMBL27736628 | 0.83 | HTR2C (0.51) | PREPNPSR1TSHRL3MBTL1HTR2C | |
| Hydrochloric Acid SCHEMBL7013165 | 0.83 | HTR2C (0.51) | PREPCTSKNPSR1TSHRL3MBTL1 | |
| SCHEMBL27757498 | 0.83 | HTR2C (0.51) | PREPNPSR1TSHRL3MBTL1HTR2C | |
| SCHEMBL8203518 | 0.83 | PREP (0.47) | KLK7KLK5PREPCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| US-9273003-B2 | Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273003-B2 | Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20140323531-A1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140323531-A1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-10-30 | — | — | US | disclosed |
| US-8637547-B2 | Compounds which inhibit members of the histone deacetylase family of enzymes and their use in the treatment of cell proliferative diseases | CHROMA THERAPEUTICS LTD. (GB) | 2014-01-28 | — | — | US | disclosed |
| CN-101541800-A | Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer | CHROMA THERAPEUTICS LTD (GB) | 2009-09-23 | — | — | CN | disclosed |
| US-20090203711-A1 | Inhibitors of P38 Map Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203711-A1 | Inhibitors of P38 Map Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203711-A1 | Inhibitors of P38 Map Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2009-08-13 | — | — | US | disclosed |
| EP-2079743-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | Chroma Therapeutics Limited (GB) | 2009-07-22 | — | — | EP | disclosed |
| EP-2016055-A1 | INHIBITORS OF P38 MAP KINASE | Chroma Therapeutics Limited (GB) | 2009-01-21 | — | — | EP | disclosed |
| WO-2008050096-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050096-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007129036-A1 | INHIBITORS OF P38 MAP KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129036-A1 | INHIBITORS OF P38 MAP KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203711-A1 | Inhibitors of P38 Map Kinase | MAPK1, MAPK3, CNKSR1 | KLK7 4628/4885KLK5 4636/4885PREP 477/4885 |
| US-20140323531-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | KLK7 3883/4885KLK5 3942/4885PREP 699/4885 |
| US-20160137594-A1 | HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | KLK7 4067/4885KLK5 4442/4885PREP 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.